Clinique Victor Hugo — Clinical Trial Site

83 Registered trials

32 Currently recruiting

Organisation

Clinique Victor Hugo

Location

Le Mans, France

Identifier

ORG-100032493

Address

Centre De Cancerologie De La Sarthe, 66 Rue De Degre, 72000, France

Departments

-
#3350: Hématologie
125008
2315 Oncology Medical
409: Hematologie
Biologie médicale
Breast Oncology
Centre Jean Bernard (Atlas), Clinique Victor Hugo
FR30004 Plateforme de Recherche, Clinique Département Investigation, Oncologie-Hematologie
Generalist Medicine
Haematology
Hématologie
Hématologie clinique
Hematology
Medecine nucleaire
Medical Oncology
Medical Oncology Department
N/A
Onco-Haematology
Onco-hématologie
ONCO-RADIOTHERAPY
ONCOLOGIE
Oncologie Médicale
Oncologie Radiothérapie
Oncologie Thérapeutique
Oncologie-Radiothérapie
oncology
Oncology - radiotherapy
Oncology – radiotherapy
Oncology and Radiotherapy
Oncology radiotherapy
Oncology-Radiotherapy
Oncoloy-Radiotherapy
Radiotherapy
Radiotherapy - oncology
Radiotherapy_ Oncology
Radiotherapy-oncology
Radiothezapy - Oncology
Service d'oncologie médicale
Service de radiothérapie

Clinical trials at this site (83)

Search interface

Effect of Copper CU64 PSMA I&T scanning to detect potential disease spread to lymph nodes in men with newly diagnosed Prostate Cancer Not authorised

2024-512754-16-00 Prostate cancer 5
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending

2024-519298-21-00 Cancer-Associated Thrombosis (CAT). 5
Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and… Recruiting

2025-522996-27-00 recurrent and/or metastatic squamous cell carcinoma of 5 2026-05-05
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting

2025-522279-27-00 Newly Diagnosed AML with an NPM1 mutation 5 2026-04-02
A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting

2023-507525-42-00 Endometrial cancer 5 2025-12-23
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting

2024-516906-47-00 Locally Advanced or Metastatic Urothelial Carcinoma 10 2025-11-28
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting

2024-513219-29-00 Renal Cell Carcinoma 5 2024-10-21
Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting

2023-504231-41-01 Locally advanced or metastatic urothelial cancer 4 2024-10-02
A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso… Recruiting

2024-511855-16-00 Onco-hematology 5 2019-07-25
Study of Taxane-Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma… Recruiting

2023-510559-41-00 Recurrent or Metastatic Squamous Cell Carcinoma of the 4 2026-06-15
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-034) Recruiting

2024-516993-31-00 Renal Cell Carcinoma 5 2026-05-11
A clinical study to find the optimal dose of an investigational treatment called BNT323 when used in combination with another investigationa… Recruiting

2024-517979-20-00 Advanced Breast Cancer Metastatic Breast Cancer 9 2026-03-04
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting

2025-521917-24-00 Treatment-Naïve Recurrent/Metastatic Head and Neck Squa 5 2026-01-21
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting

2024-517653-27-00 Prostate Cancer 4 2025-12-17
A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting

2024-513586-39-00 Prostate Cancer 5 2025-12-10
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting

2025-520555-89-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-11-14
IFCT-2401 SPORADIC a multicenter randomized open label phase II study evaluating the efficacy and the tolerance of adding cemiplimab to Sequ… Recruiting

2024-517316-29-00 Unresectable stage III Non-Small Cell Lung Cancer 4 2025-11-07
Clinical trial comparing induction treatment with EGFR-ADC MRG003 alone or in combination with the anti PD1 Pucotenlimab, followed by radioc… Recruiting

2023-510558-18-00 locally advanced head and neck squamous cell carcinoma 4 2025-10-13
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel… Recruiting

2024-510772-20-00 Rectal cancer locally advanced with microsatellite unst 4 2025-02-06
C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant… Recruiting

2024-511652-40-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-02-05
A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting

2023-510322-32-00 patients with incurable, metastatic/recurrent head and 5 2025-01-27
A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting

2023-510323-30-00 First-line treatment of recurrent or metastatic PD-L1+ 5 2025-01-24